Relevant bibliographies by topics / Senile dementia Treatment New Zealand

Academic literature on the topic 'Senile dementia Treatment New Zealand'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Senile dementia Treatment New Zealand.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Senile dementia Treatment New Zealand"

1

Keim, Kevin L., and B�la Kiss. "New drug strategies in the treatment of senile dementia of different origin." Drug Development Research 14, no. 3-4 (1988): 181. http://dx.doi.org/10.1002/ddr.430140302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schmidt, Joachim, Hans-Dieter Fischer, and Christian Wustmann. "Strategies and new aspects in the pharmacology of drugs for the treatment of senile dementia." Drug Development Research 14, no. 3-4 (1988): 251–62. http://dx.doi.org/10.1002/ddr.430140317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fekete, Gy�rgy. "New drug strategies in the treatment of senile dementia of different origins: Satellite symposium of 2nd world congress of neuroscience." Drug Development Research 14, no. 3-4 (1988): 183–84. http://dx.doi.org/10.1002/ddr.430140303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Maiese, Kenneth, Zhao Zhong Chong, Jinling Hou, and Yan Chen Shang. "New Strategies for Alzheimer Disease and Cognitive Impairment." Oxidative Medicine and Cellular Longevity 2, no. 5 (2009): 279–89. http://dx.doi.org/10.4161/oxim.2.5.9990.

Full text
Abstract:
Approximately five million people suffer with Alzheimer disease (AD) and more than twenty-four million people are diagnosed with AD, pre-senile dementia, and other disorders of cognitive loss worldwide. Furthermore, the annual cost per patient with AD can approach $200,000 with an annual population aggregate cost of $100 billion. Yet, complete therapeutic prevention or reversal of neurovascular injury during AD and cognitive loss is not achievable despite the current understanding of the cellular pathways that modulate nervous system injury during these disorders. As a result, identification of novel therapeutic targets for the treatment of neurovascular injury would be extremely beneficial to reduce or eliminate disability from diseases that lead to cognitive loss or impairment. Here we describe the capacity of intrinsic cellular mechanisms for the novel pathways of erythropoietin and forkhead transcription factors that may offer not only new strategies for disorders such as AD and cognitive loss, but also function as biomarkers for disease onset and progression.
APA, Harvard, Vancouver, ISO, and other styles
5

Shevtsova, E. F., D. V. Vinogradova, M. E. Neganova, P. N. Shevtsov, B. V. Lednev, and S. O. Bachurin. "Mitochondria are an Important Target in the Search for new Drugs for the Treatment of Alzheimer′s Disease and Senile Dementia." Biomedical Chemistry: Research and Methods 1, no. 3 (2018): e00058. http://dx.doi.org/10.18097/bmcrm00058.

Full text
Abstract:
The review and summarizes own and literature data about the role of mitochondria as the important target in the search for drugs for the treatment of neurodegenerative diseases. Aging is a major risk factor for sporadic forms of various neurodegenerative diseases, including Alzheimer′s disease. One of the most argued and currently accepted theories is the Mitochondrial Free Radical Theory of Aging. Mitochondrial hypotheses of the development of sporadic forms of neurodegenerative diseases particularly Alzheimer′s disease, are closely connected with it. Impairments of mitochondrial functions lead to a decrease in their ability to regulate calcium homeostasis in the cell and to a decrease in the threshold for the induction of mitochondrial permeability transition (MPT) pores. MPT inhibitors can be considered as a promising approach to the treatment of neurodegenerative diseases, since these drugs can not only exhibit the properties of neuroprotectors, but also can provide normalization of synaptic activity due to increased calcium capacity of mitochondria. The review presents data on the number of MPT inhibitors, including endogenous compounds melatonin and N-acetylserotonin, their bioisosteric analogue Dimebon and a number of other compounds. The use of mitochondria as a basis for the formation of screening strategy for the search for compounds for the treatment of neurodegenerative diseases is of particular interest – both as a test of their potential toxicity, and as a basis for the creation of metabolic stimulants and drugs with neuroprotective and cognitive-stimulating effect.
APA, Harvard, Vancouver, ISO, and other styles
6

Pardo-Moreno, Teresa, Anabel González-Acedo, Antonio Rivas-Domínguez, Victoria García-Morales, Francisco Jose García-Cozar, Juan Jose Ramos-Rodríguez, and Lucía Melguizo-Rodríguez. "Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives." Pharmaceutics 14, no. 6 (May 24, 2022): 1117. http://dx.doi.org/10.3390/pharmaceutics14061117.

Full text
Abstract:
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
APA, Harvard, Vancouver, ISO, and other styles
7

Swakowska, Katarzyna, and Anna Staniszewska. "Alzheimer's disease: classification and diagnosis criteria." Journal of Education, Health and Sport 11, no. 7 (July 5, 2021): 22–29. http://dx.doi.org/10.12775/jehs.2021.11.07.002.

Full text
Abstract:
In recent years, the intensity of population aging has increased and the incidence of senile diseases, including dementia, has significantly increased. With the aging of populations in Europe, knowledge about the detection and diagnosis of dementia has increased in the last decade. Due to the increase in the number of patients, new therapies and precise diagnostic criteria have been introduced, contributing to faster diagnosis of the disease. Alzheimer's disease (AD) is the biggest cause of dementia in old age. It is characterized by progressive cognitive deficits, especially memory, and disorders such as: apathy, agitation and psychotic symptoms. Alzhaimer's disease is a degenerative brain disease caused by the deposition of pathological B-amyloid protein tau and alpha-synuclein in the brain, causing atrophy of neurons and their connections. The basis for diagnosis of dementia in the course of Alzheimer's disease are ICD-10 or DSM-IV criteria. The clinical course and symptoms in the course of AD are defined by the Global Deterioration Scale (GDS), the scale also determines the stage of the disease. Acetylcholinesterase inhibitor drugs and memantine are used to treat the symptoms of Alzheimer's disease. Prompt diagnosis and treatment significantly delays the progression of the disease and helps to prolong normal functioning of the patient.
APA, Harvard, Vancouver, ISO, and other styles
8

Greve, Melissa, and Daniel O'Connor. "A survey of Australian and New Zealand old age psychiatrists' preferred medications to treat behavioral and psychological symptoms of dementia (BPSD)." International Psychogeriatrics 17, no. 2 (June 2005): 195–205. http://dx.doi.org/10.1017/s1041610205001481.

Full text
Abstract:
Background: People with behavioral and psychological symptoms of dementia (BPSD) are often prescribed psychotropic medications. There is little evidence that one class of medication is more effective and safer than another and so expert opinion plays an important role in shaping local practice. In an earlier U.S. survey of psychiatrists and neurologists, limited consensus emerged regarding the pharmacological management of BPSD. We repeated this study to check consensus levels in Australia and New Zealand, following the introduction of newer atypical neuroleptics, antidepressants and cholinesterase inhibitors, and to identify areas where drug trials will be of greatest benefit.Methods: A brief structured survey, similar to one used in the U.S.A., was posted to a random sample of members of the Australian and New Zealand Faculty of Psychiatry of Old Age.Results: We received 106 replies (71% response). Respondents, who had 14 years' experience on average, rated atypical neuroleptics as their treatment of choice for dementia complicated by psychosis, verbal aggression, physical aggression, sundowning and persistent yelling. Opinions varied widely regarding the management of other symptoms and the role of second-line treatments.Conclusion: Atypical neuroleptics were preferred by most respondents for treatment of most BPSD. These views, while based on considerable clinical experience, have only limited backing from published reports, and head-to-head studies of available treatments are required to ensure that clinical practice has scientific support.
APA, Harvard, Vancouver, ISO, and other styles
9

Weiner, Michael, Susan Wells, and Ngaire Kerse. "Perspectives of general practitioners towards evaluation and treatment of cardiovascular diseases among older people." Journal of Primary Health Care 1, no. 3 (2009): 198. http://dx.doi.org/10.1071/hc09198.

Full text
Abstract:
INTRODUCTION: Risk of cardiovascular disease (CVD) events increases with age. With treatment, individuals with highest risk accrue greater absolute risk reduction. New Zealand’s CVD guidelines provide no upper age limit for risk assessment. Guidance for treating those over 75 years is limited. Little is known about GPs’ attitudes regarding assessing and managing cardiovascular risk among older people. METHODS: A 39-item questionnaire including three cases representing various risk was developed and administered to 500 GPs randomly selected from a registry. RESULTS: Of the GPs, 379 were eligible; 86 (22%) responded to the questionnaire. Most were male (57%), between 40 and 59 years of age (74%), of European ethnicity (57%), had a medical degree from NZ (60%), and had been practising for at least 10 years (98%). Respondents were less likely to assess risk with increasing patient age and more likely to manage risk according to individual risk factors, rather than absolute risk. Marked variation occurred in intent to assess risk for a patient aged 78 years, according to living environment, co-morbidity, and functional status. In general, respondents indicated that they would usually assess risk for a 78-year-old community-dwelling patient without dementia but not for such a patient living in residential care or with dementia. DISCUSSION: This is New Zealand’s first report of GPs’ perspectives about assessing and managing CVD risk for older patients. Findings are consistent with international studies. More support and training in lifestyle assessment is needed, as well as clearer guidance for assessing and managing risk among older patients. KEYWORDS: Cardiovascular diseases; risk assessment; preventive medicine; geriatrics; public health
APA, Harvard, Vancouver, ISO, and other styles
10

Frenchman, I. Barton, and Theodore Prince. "Clinical Experience With Risperidone, Haloperidol, and Thioridazine for Dementia-Associated Behavioral Disturbances." International Psychogeriatrics 9, no. 4 (December 1997): 431–35. http://dx.doi.org/10.1017/s1041610297004560.

Full text
Abstract:
The efficacy and safety of risperidone, haloperidol, and thioridazine for treating dementia-associated behavioral disturbances were evaluated in a retrospective study of 186 patients aged 65 years or older with DSM-III-R or DSM-IV diagnoses of Alzheimer's dementia, senile dementia NOS, or organic brain syndrome. Study patients were selected from the charts of 12,000 residents of 60 long-term-care facilities in New Jersey if they were treated with one of the three agents for behaviours dangerous to themselves or others. The 186 selected patients included 60 treatedwith risperidone (mean, 1 mg/day), 83 with haloperidol (mean, 2 mg/day), and 43 with thioridazine (mean, 33 mg/day). Target behaviors were violence (74 patients), shouting (31), delusions (26), paranoia (19), pacing (3), and mixed behaviors (33). Target behaviors improved in 94% of patients given risperidone, 65% given haloperidol, and 67% given thioridazine (p < .001). Treatment failures (treatment discontinued in patients because of side effects or no improvement) were more frequent in patients started on haloperidol (28) or thioridazine (15) than on risperidone (3). Extrapyramidal symptoms were reported in 7% of patients taking risperidone, 22% taking haloperidol, and 18% taking thioridazine. Safe, effective doses are readily achieved with risperidone but difficult to achieve with haloperidol or thioridazine because their effective doses often cause unacceptable side effects. These data are only suggestive because no guidelines exist for defining or measuring behavioral disturbances or for how they are affected by social, psychological, or environmental factors.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Senile dementia Treatment New Zealand"

1

Shamoian, C. A. "What is New and what is Necessary in Dementia Research?" In Diagnosis and Treatment of Senile Dementia, 17–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-46658-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Irie, Tsunemasa, Kazuichi Natori, Yuko Okazaki, and Junki Katsube. "SM-10888, a New Drug Candidate for Treatment of Senile Dementia of the Alzheimer Type." In Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases, 403–7. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5847-3_82.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Senile dementia Treatment New Zealand"

1

Requião, Letícia Escorse, Giulia Freitas, Mayanna Macedo, Hanny Gondim, Blenda Antunes, and Bruno Lopes. "Monoclonal antibodies: a new trend for the treatment of Alzheimer’s disease?" In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.439.

Full text
Abstract:
Introduction: Alzheimer’s disease (AD) is the main form of senile dementia. Most of the supposedly disease-modifying treatments in development are directed against the β-amyloid peptide, the administration of exogenous anti-Aβ monoclonal antibodies is a passive immunization strategy aimed at resolving the aggregation of this substance. Objective: Analyze the effectiveness of monoclonal antibodies in the treatment of Alzheimer’s disease. Methods: This is a literature review, based on randomized clinical trials published between 2014 and 2021. The search was conducted in the PubMed database. Results: According to the eligibility criteria, 10 articles were selected. Two of the randomized, double-blind, placebo-controlled phase III studies, one published in 2018 and the other published in 2016, evaluated the intervention with Solanezumab and Bapineuzumab, respectively. Both were not shown to be statistically significant (P = 0.10) for the outcome improvement of the score in the cognitive subscale of 14 and 11 items “Alzheimer’s Disease Assessment Scale” (ADAS-cog14 / 11). However, in a phase II randomized placebo-controlled clinical trial, published in 2021, the use of Donanemab in patients with early Alzheimer’s disease resulted in statistically significant cognitive and functional improvement (P = 0.04) for the outcome change in the scale “Integrated Alzheimer’s Disease Rating” (iADR). Conclusion: Although the use of Donanemab has resulted in cognitive and functional improvement, randomized, double-blind, placebo-controlled, phase III clinical trials need to be conducted to prove the efficacy and safety of its use in clinical practice. Other monoclonal antibodies evaluated did not demonstrate evidence of benefit.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Senile dementia Treatment New Zealand' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography